Nemaura Medical Inc.: Nasdaq/NYSE listing notice — Nemaura Medical receives Nasdaq delisting notices for MVLS and bid price non-compliance

Nemaura Medical Inc.

Received notice on Oct 3-4, 2023 for failing to meet $35M MVLS and $1 bid price requirements.
Grace periods expired Oct 2 (MVLS) and Oct 3 (bid price) without regaining compliance.
Company intends to request a hearing before Nasdaq Hearings Panel to stay delisting.
Panel may grant extension until April 1, 2024; no assurance of continued listing.
Common stock (NMRD) expected to trade on Nasdaq through hearings process.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Nemaura Medical Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

October 3, 2023. On October 3 and 4, 2023, respectively, the Company received written notices from the Nasdaq Staff indicating that the Company had not regained compliance with the MVLS and Bid Price requirements, and that the Company’s common stock would be subject to delisting from The Nasdaq Capital Market unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”). Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration o

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Nemaura Medical Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

al Market. Accordingly, the Company was granted a grace period that expired on October 2, 2023. In addition, on April 6, 2023, the Company received a written notice that the Company was not in compliance with the $1 bid price (“Bid Price”) requirement for continued listing set forth in Listing Rule 5550(a)(2) and was granted a grace period that expired on October 3, 2023. On October 3 and 4, 2023, respectively, the Company received written notices from the Nasdaq Staff indicating that the Company had not regained compliance with the MVLS and Bid Price requirements, and that the Company’s commo

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001079973-23-001393

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.